Anika Therapeutics, Inc.
ANIK
$9.76
-$0.12-1.22%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.42% | 7.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.42% | 7.84% | |||
| Cost of Revenue | -11.71% | 20.62% | |||
| Gross Profit | 8.50% | -2.17% | |||
| SG&A Expenses | -2.94% | -5.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.16% | 6.39% | |||
| Operating Income | 22.66% | 2.43% | |||
| Income Before Tax | 43.62% | -2.51% | |||
| Income Tax Expenses | 37.89% | 665.17% | |||
| Earnings from Continuing Operations | 31.68% | -17.41% | |||
| Earnings from Discontinued Operations | 24.96% | 173.99% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.34% | 18.53% | |||
| EBIT | 22.66% | 2.43% | |||
| EBITDA | 37.18% | -8.21% | |||
| EPS Basic | 41.57% | 18.90% | |||
| Normalized Basic EPS | 43.86% | -2.07% | |||
| EPS Diluted | 43.01% | 17.62% | |||
| Normalized Diluted EPS | 43.23% | -0.95% | |||
| Average Basic Shares Outstanding | 0.38% | 0.47% | |||
| Average Diluted Shares Outstanding | -0.68% | 1.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||